IP Library Patent Application 14281638
Patent Application
App. No. 14/281,638

SYSTEMS, METHODS, AND COMPOSITIONS FOR CROSS-LINKING

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/281,638
Abstract

Various agents and additives for cross-linking treatments are identified in disclosed studies. The characteristics of the various agents and additives may be advantageously employed in formulations applied in cross-linking treatments of the eye. In some embodiments, riboflavin is combined with Iron(II) to enhance the cross-linking activity generated by the riboflavin. In other embodiments, cross-linking treatments employ an Iron(II) solution in combination with a hydrogen peroxide pre-soak. In yet other embodiments, 2,3-butanedione is employed to increase the efficacy of corneal cross-linking with a photosensitizer, such as riboflavin. In further embodiments, folic acid is employed in combination with a photosensitizer, such as riboflavin, to enhance cross-linking activity. In yet further embodiments, 2,3-butanedione, folic acid, a quinoxaline, a quinoline, dibucaine, Methotrexate, menadione, or a derivative thereof is applied as a cross-linking agent.

Claims (31)

1 . A composition for applying therapy to a cornea of an eye, comprising:

a cross-linking agent that generates cross-linking activity in the cornea in response to exposure to a photo-activating light; and

at least one additive different from the cross-linking agent and selected from the group consisting of iron, copper, manganese, chromium, vanadium, aluminum, cobalt, mercury, cadmium, nickel, arsenic, 2,3-butanedione, and folic acid, wherein the at least one additive enhances the cross-linking activity generated by the cross-linking agent.

2 . The composition of claim 1 , wherein the cross-linking agent is selected from the group consisting of riboflavin, 2,3-butanedione, folic acid, quinoxalines, quinolines, dibucaine, Methotrexate, menadione, and derivatives thereof.

3 . The composition of claim 1 , wherein the at least one additive is iron.

4 . The composition of claim 3 , wherein the iron is provided by FeSO 4 .

5 . The composition of claim 1 , wherein the at least one additive is 2,3-butanedione.

6 . The composition of claim 1 , wherein the at least one additive is folic acid.

7 . A method for applying therapy to a cornea of an eye, comprising:

applying a composition to the cornea, the composition including

a cross-linking agent that generates cross-linking activity in the cornea in response to exposure to a photoactivating light; and

at least one additive different from the cross-linking agent and selected from the group consisting of iron, copper, manganese, chromium, vanadium, aluminum, cobalt, mercury, cadmium, nickel, arsenic, 2,3-butanedione, and folic acid; and

applying photoactivating light to the cornea to generate cross-linking activity in the cornea,

wherein the at least one additive enhances the cross-linking activity generated by the cross-linking agent.

8 . The method of claim 7 , wherein the cross-linking agent is selected from the group consisting of riboflavin, 2,3-butanedione, folic acid, quinoxalines, quinolines, dibucaine, Methotrexate, menadione, and derivatives thereof.

9 . The method of claim 7 , wherein the at least one additive is iron.

10 . The method of claim 9 , wherein the iron is provided by FeSO 4 .

11 . The method of claim 7 , wherein the at least one additive is 2,3-butanedione.

12 . The method of claim 7 , wherein the at least one additive is folic acid.

13 . The method of claim 7 , wherein the photoactivating light is ultraviolet light.

14 . The method of claim 7 , wherein the photoactivating light is pulsed.

15 . The method of claim 7 , further comprising applying oxygen to the cornea.

16 . A method for applying therapy to a cornea of an eye, comprising:

applying a cross-linking agent to the cornea, the cross-linking agent being selected from the group consisting of 2,3-butanedione, folic acid, quinoxalines, quinolines, dibucaine, Methotrexate, menadione, and derivatives thereof; and

applying photoactivating light to the cornea to generate cross-linking activity in the cornea.

17 . The method of claim 16 , wherein the photoactivating light is ultraviolet light.

18 . The method of claim 16 , wherein the photoactivating light is pulsed.

19 . The method of claim 16 , further comprising applying oxygen to the cornea to control the cross-linking activity generated by the cross-linking agent.

20 . A method for applying therapy to a cornea of an eye, comprising:

applying a hydrogen peroxide to the cornea; and

applying an iron solution to the cornea after applying the hydrogen peroxide, the hydrogen peroxide and iron solution combining to generate cross-linking activity in the cornea.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Nov 21, 2019
From: ORBIMED ROYALTY OPPORTUNITIES II, LP
To: AVEDRO, INC.
Reel/Frame 051080/0756 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT SERIAL NO. 14/140,184 PREVIOUSLY RECORDED AT REEL: 042167 FRAME: 0671. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 1, 2017
From: AVEDRO, INC.
To: ORBIMED ROYALTY OPPORTUNITIES II, LP
Reel/Frame 042390/0659 →
SECURITY INTEREST Recorded Apr 27, 2017
From: AVEDRO, INC.
To: ORBIMED ROYALTY OPPORTUNITIES II, LP
Reel/Frame 042167/0671 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2014
From: KAMAEV, PAVEL; FRIEDMAN, MARC D.; SHERR, EVAN; MULLER, DAVID
To: AVEDRO, INC.
Reel/Frame 033425/0702 →